CARA vs. JAN, PMN, OCUP, MRKR, UNCY, BCTX, XLO, BOLT, FBIO, and NXTC
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include JanOne (JAN), ProMIS Neurosciences (PMN), Ocuphire Pharma (OCUP), Marker Therapeutics (MRKR), Unicycive Therapeutics (UNCY), BriaCell Therapeutics (BCTX), Xilio Therapeutics (XLO), Bolt Biotherapeutics (BOLT), Fortress Biotech (FBIO), and NextCure (NXTC). These companies are all part of the "pharmaceutical preparations" industry.
Cara Therapeutics (NASDAQ:CARA) and JanOne (NASDAQ:JAN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
Cara Therapeutics presently has a consensus target price of $9.75, suggesting a potential upside of 1,324.81%. Given Cara Therapeutics' higher possible upside, equities research analysts plainly believe Cara Therapeutics is more favorable than JanOne.
JanOne has higher revenue and earnings than Cara Therapeutics.
In the previous week, Cara Therapeutics had 1 more articles in the media than JanOne. MarketBeat recorded 3 mentions for Cara Therapeutics and 2 mentions for JanOne. JanOne's average media sentiment score of 0.50 beat Cara Therapeutics' score of 0.46 indicating that JanOne is being referred to more favorably in the news media.
44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 6.3% of JanOne shares are owned by institutional investors. 4.2% of Cara Therapeutics shares are owned by company insiders. Comparatively, 3.0% of JanOne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cara Therapeutics received 664 more outperform votes than JanOne when rated by MarketBeat users.
Cara Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, JanOne has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.
JanOne has a net margin of 0.00% compared to Cara Therapeutics' net margin of -565.21%. Cara Therapeutics' return on equity of -122.10% beat JanOne's return on equity.
Summary
Cara Therapeutics beats JanOne on 8 of the 14 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
